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Abstract Membrane-bound solute carriers (SLCs) are essen-
tial as they maintain several physiological functions, such as
nutrient uptake, ion transport and waste removal. The SLC
family comprise about 400 transporters, and we have identi-
fied two new putative family members, major facilitator su-
perfamily domain containing 1 (MFSD1) and 3 (MFSD3).
They cluster phylogenetically with SLCs of MFS type, and
both proteins are conserved in chordates, whileMFSD1 is also
found in fruit fly. Based on homology modelling, we predict
12 transmembrane regions, a common feature for MFS trans-
porters. The genes are expressed in abundance in mice, with
specific protein staining along the plasma membrane in neu-
rons. Deprivingmouse embryonic primary cortex cells of ami-
no acids resulted in upregulation of Mfsd1, whereas Mfsd3 is
unaltered. Furthermore, in vivo, Mfsd1 and Mfsd3 are down-
regulated in anterior brain sections in mice subjected to star-
vation, while upregulated specifically in brainstem. Mfsd3 is
also attenuated in cerebellum after starvation. In mice raised
on high-fat diet, Mfsd1 was specifically downregulated in
brainstem and hypothalamus, while Mfsd3 was reduced con-
sistently throughout the brain.
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Introduction
Membrane-bound transporters are physiologically important
as they keep the homeostasis of soluble molecules within cel-
lular compartments, and it is crucial to study their basic his-
tology and function to understand the human body. The solute
carrier (SLC) superfamily is the largest group of membrane-
bound transporters in human and it includes 395 members,
divided in 52 families (Hediger et al. 2004). SLCs utilize
ATP-independent mechanisms to move nutrients, ions, drugs
and waste over lipid membranes, and SLC deficiencies are
associated with several human diseases (Hediger et al. 2013;
Lin et al. 2015).
SLC proteins are grouped into Pfam clans based on func-
tional domains, where the two largest clans, the major facili-
tator superfamily (MFS) and the amino acid-polyamine
organocation (APC) clan (Hoglund et al. 2011), contain more
than half of all SLC families. The MFS clan includes 16 SLC
families, and all theMFS domain (MFSD)# proteins. Here, we
are studying two novel MFSD# proteins, major facilitator su-
perfamily domain containing 1 (MFSD1) and 3 (MFSD3). In
humans, MFSD# transporters are commonly referred to as
atypical SLCs, since they share high sequence similarity and
evolutionary history with SLCs (Fredriksson et al. 2008;
Perland et al. 2016; Sreedharan et al. 2011). MFSD# proteins
are usually identified from large-scale genome annotation pro-
jects (Fredriksson et al. 2008) and named according to the
HUGO Gene Nomenclature Committee (HGNC) nomencla-
ture (Gray et al. 2016). At present, there are 17MFSD# entries
in the HGNC database and most are still orphans regarding
expression, substrate and/or mechanism. However, MFSD2a
was recently characterized as an omega 3 fatty acid transport-
er, located in endothelial cells in the blood-brain barrier in
mice (Nguyen et al. 2014), MFSD4B is a sugar transporter
in rat kidneys (Horiba et al. 2003) and human MFSD10
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transport organic anions over the plasmamembrane (Ushijima
et al. 2008). MFSD7 (SLC49A3) is already classified into the
SLC49 family based on sequence identity (Khan and Quigley
2013), but its expression and substrate is unknown.
Furthermore, MFSD5 and MFSD11(Perland et al. 2016) are
located in the plasma membrane (Perland et al. 2016), where
they are suggested to be involved in regulating energy homeo-
stasis (Perland et al. 2016). MFSD8 is expressed in lysosomal
membranes (Damme et al. 2014; Siintola et al. 2007), and the
messenger RNA (mRNA) ofMfsd1 is expressed in various rat
organs (Sreedharan et al. 2011). Looking at molecular-level
information from the Kyoto Encyclopaedia of Genes and
Genome (Kanehisa et al. 2016), MFSD1 is a predicted sugar
transporter and MFSD3 a predicted acetyl-CoA transporter
(Kanehisa et al. 2016).
Here, we present phylogenetic, homologic and histological
data of MFSD1 and MFSD3. A phylogenetic tree was built to
visualize the relationship between MFSD1 and MFSD3 and
SLCs of MFS type, and global alignments were run against
their evolutionary most closely related SLCs to investigate
possible family affiliations. Secondary and tertiary protein
models were built to study their transporter possibilities.
Immunohistochemistry was performed to determine where
the protein expression of MFSD1 and MFSD3 is in mouse
brain, with focus on cell type specificity and subcellular loca-
tion. Furthermore, we studied how nutrient availability affect-
ed the gene levels, both in mouse brain following starvation
and high-fat diet (HFD) and in primary embryonic cortex cells
following partial amino acid starvation.
Material and Methods
Phylogenetic Analysis
Human SLC amino acid sequences of MFS type (SLC2, 15,
16, 17, 18, 19, 22, 29, 33, 37, 40, 43, 45, 46 and SLCO),
were downloaded together with human proteins including
the MFS motif (MFSD1, MFSD2a, MFSD2b, MFSD3,
MFSD5, MFSD7, MFSD8, MFSD10, MFSD11, MFSD13,
SV2A, SV2B, SV2C, SVOP and SVOPL) f rom
(Cunningham et al. 2015) (Ensembl release 84). MFSD1
and MFSD3 orthologous sequences were also obtained
from the ENSEMBL database (listed in Table 1). These se-
quences were combined into a multiple PSI/TM sequence
alignment using tcoffee (Notredame et al. 2000). The phy-
logenetic relationships between the sequences were inferred
using the Bayesian approach as implemented in mrBayes
3.2.2 (Huelsenbeck and Ronquist 2001; Ronquist et al.
2012) to obtain the tree. The analysis was run via the
Beagle library (Ayres et al. 2012) on an NVIDA 980Ti
graphics card, and it was run on six chains (five heated and
one cold) with two runs in parallel (n runs = 2) under the
mixed amino acid model with eight gamma categories and
invgamma as gamma rates for a total of 2,000,000
generations.
Sequence and Homology Modelling
To investigate the hypothesis thatMFSD1 andMFSD3 indeed
we r e SLCs , we r e t r i e v e d t h e human MFSD1
(ENST00000415822.6) and MFSD3 (ENST00000301327.4)
protein sequences and performed a prediction of their trans-
membrane sequences (TMS) using TMHMM server (v. 2.0;
http://www.cbs.dtu.dk/services/TMHMM/). We then
compared the TMS prediction with 3D homology models, to
evaluate their possibility to actually span membranes; each
amino acid in the membrane helices was identified and
compared between the secondary and tertiary structure. The
Swiss model fully automated homology program (Biasini
et al. 2014) first identified MFSD1 andMFSD3 asMFS trans-
porters and subsequently used the glycerol-3-phosphate MFS
transporter (Huang et al. 2003) as template for MFSD1, and
the YajR MFS transporter (Jiang et al. 2013) as template for
MFSD3, when building the homology models. The tertiary
protein structures were finalized using Swiss-Pdb Viewer
(Guex and Peitsch 1997).
Finally, we investigated the sequence similarities between
MFSD1 and MFSD3 and their phylogenetically closest rela-
tives, the SLC29 and SLC33 family, respectively, using a
global pairwise sequence alignment, using the Needleman-
Wunsch algorithm (Li et al. 2015).
Animal Handling
All experiments including mice were approved by the local
ethical committee in Uppsala (Uppsala Djurförsöksetiska
Nämnd, Uppsala district court) (Permit Number C419/12,
C39/16 and C67/13) and conformed to the guidelines of
European Communities Council Directive (2010/63) prior ex-
ecution. Adult C57Bl6/J mice (Taconic M&B, Denmark)
were used. All mice had free access to water and standard
R3 chow (Lantmännen) unless otherwise stated. They were
housed in a temperature-, light- and humidity-controlled room
and euthanasia was performed during the light period by either
cervical dislocation or transcardiac perfusion.
Tissue Isolation, RNA Extraction and cDNA Synthesis
from Wild-Type and Food-Restricted Mice
Material for an RNA panel including peripheral and central
organs from adult mice was previously made (Perland et al.
2016) and subsequently used herein. Males were used for the
panel with the addition of females for collection of female
genitals. Additional mice were subjected to (1) normal chow,
(2) 24-h starvation or (3) high-fat western diet (R368,
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Lantmännen) for 8 weeks before euthanasia, all according to
(Perland et al. 2016). There was a 38 ± 9 % increase in weight
in the obese group compared to a 12 ± 2.3 % increase in
controls. n = 4 per diet for the specific brain areas: brainstem
cortex, cerebellum, hypothalamus and striatum. The remain-
ing brains (n = 6 for controls, n = 4 for starved and n = 6 in the
HFD) were cut into larger brain sections using a brain matrix
(Alto, 1 mm).
Briefly, mice were euthanized by cervical dislocation and
collected tissues were preserved in RNA-later (QIAGEN) and
the tissues were homogenized using 1 mm RNAse-free glass
beads and a bullet blender (Averill Park, USA). The RNAwas
extracted from individual samples using Absolutely RNA
Miniprep Kit (Agilent Technologies) following manufac-
turer’s instructions. A Heraesus Fresco 21 centrifuge was used
at maximum speed at room temperature (RT) to remove debris
by prefilter spin cups followed by RNA collection in binding
cups. The RNAwas washed and finally eluted. Concentrations
were measured using an ND-1000 spectrophotometer
(NanoDrop Technologies). The Applied Biosystems High-
Capacity RNA-to-cDNA kit (Invitrogen) was then used for
complementary DNA (cDNA) synthesis following manufac-
turer’s instructions. Two-microgram RNAwas added to each
cDNA synthesis reaction. The reaction was performed at
37 °C for 1 h, followed by 5 min incubation at 95 °C.
cDNA from the same sample, but from different animals, were
pooled and diluted to 5 ng/μl RNA in sterile water.
Primers and Quantitative Real-Time PCR
The tissue distribution of Mfsd1 and Mfsd3 were determined
using quantitative real-time PCR (qPCR). Primers were de-
signed using Beacon Design 8 (Premier Biosoft, Palo Alto).
Fo r s amp l e amp l i f i c a t i on : Mfsd1 f o rwa r d 5 ′ -
gacctctgtaaggatctg-3′, reverse 5′-tgctataatacaaaggaaagg-3′
and Mfsd3 forward 5′-atttctggtcccagtgtg-3′, reverse 5′-
gatgaacagtcagggtct-3. Reference genes: glyceraldehyde-3-
phospha te dehydrogenase (Gapdh ) fo rward 5 ′ -
gccttccgtgttcctacc-3′, reverse 5′-gcctgcttcaccaccttc-3′; beta tu-
bulin 4B (bTub) forward 5′-agtgctcctcttctacag-3′, reverse 5′-
tatctccgtggtaagtgc-3′; ribosomal protein L19 (Rpl19); forward
5′-aatcgccaatgccaactc-3′, reverse 5′-ggaatggacagtcacagg-3′;
histone cluster 1 (H3a) forward 5′-ccttgtgggtctgtttga-3′, re-
verse 5′-cagttggatgtccttggg-3′; peptidylpropyl isomeras A
(Cyclo) forward 5′-tttgggaaggtgaaagaagg-3′, reverse 5′-
acagaaggaatggtttgatgg-3′; and actin-related protein 1B (Actb)
forward 5 ′-ccttcttgggtatggaatcctgtg-3 ′ , reverse 5 ′-
cagcactgtgttggcatagagg-3′.
One-microliter pooled cDNA (5 ng/μl RNA) was used per
qPCR reaction. The qPCR mastermix contained 2× DreamTaq
Buffer (Thermo Fisher Scientific), 0.2μl 20mMdNTP, 0.05μl
of both forward and reverse primer (100 pmol/μl), 0.5 μl of
SYBRGreen (1:10,000; Invitrogen) in TE buffer (pH 7.8), 1μl
dimethyl sulfoxide (Sigma-Aldrich) and 0.08 μl DreamTaq
polymerase (5 U/μl, Thermo Fisher Scientific). The volume
was adjusted to 20 μl with sterile water. The reactions were
run on iCycler real-time detection instrument (Bio-Rad
Laboratories) and followed these conditions: initial denatur-
ation for 30 s at 95 °C followed by 45 cycles of 10 s at
95 °C, 30 s at 55–61 °C (optimal temperature for each primer
pair) and 30 s at 72 °C. Thereafter, a melting curve was per-
formed by increasing the temperature 0.5 °C per cycle, during
81 cycles at 10-s intervals, starting from 55 °C. All reactions
were performed in triplicates, and negative controls were in-
cluded on each plate. All experiments were repeated twice.
Data Analysis and Relative Expression Calculations
CT values were obtained from the MyIQ (Bio-Rad
Laboratories) software. Primer efficiencies were calculated
using LinRegPCR software, followed by Grubbs test
(GraphPad software) to remove outliers in the efficiency cal-
culations. The GeNorm protocol (Vandesompele et al. 2002)
was used to detect which reference genes were stable. The
Table 1 MFSD1 and MFSD3
orthologue sequences identified
in Ensembl (version 84)










A. carolinensis MFSD1 ENSACAT00000006961 MFSD3 ENSACAT00000010595
D. melanogaster CG8602 FBtr0076884 – –
CG12194 FBtr0332476 – –
D. rerio mfsd1 ENSDART00000163827 MFSD3 ENSDART00000144995
G. gallus MFSD1 ENSGALT00000015632 – –
G. aculeatus mfsd1 ENSGACT00000013516 – –
M. musculus Mfsd1 ENSMUST00000029344 Mfsd3 ENSMUST00000019224
T. rubripes mfsd1 ENSTRUT00000009506 – –
X. tropicalis MFSD1 ENSXETT00000060684 – –
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geometric means of the stable reference genes were used to
normalize the expression of Mfsd1 and Mfsd3. For the wild-
type (wt) panel following reference genes were used: Gapdh,
bTub, Rpl19, Cyclo and Actb. The samples from mice raised
on various diets were normalized against these genes:Gapdh,
H3a and Actb. The duplicates in experimental set ups were
analysed separately, and the normalized mRNA levels ±SD
were plotted. Unpaired t tests were performed using GraphPad
Prism 5 between the control group and the starved group or
the HFD group for each brain section/region. The significance
levels were Bonferroni corrected for multiple testing and the
significance levels was set to *p ≤ 0.0493, **p ≤ 0.00998 and
***p ≤ 0.001.
Western Blot
A protein fraction from mouse brain was used as western blot
samples prepared as described in (Perland et al. 2016).
Proteins were mixed with Laemmeli Sample Buffer (Bio-
Rad) and 2-mercaptoethanol (Fluka) and loaded onto a 4–
15 % TGX Miniprotean gel (Bio-Rad). A pre stained molec-
ular weight marker was used as reference (Thermo Fisher).
The electrophoresis was run at 200 V to separate the proteins
before blotted onto PVDF membrane (Immobilon-P,
Millipore) at 4 °C at 50 V for 1 h. The membrane was blocked
for 1 h in 5 % milk (Bio-Rad) diluted in TTBS prior primary
antibody incubation at 4 °C overnight. Anti-MFSD1 (1:200,
rabbit, cat. no: SAB3500575, Sigma-Aldrich) and Anti-
MFSD3 (1:500, rabbit, cat. no: AV51707, Sigma-Aldrich)
were used. The membranes were washed before incubated
for 1 h at RT in secondary HRP coupled anti-rabbit
(Invitrogen) or HRP coupled anti-goat (Invitrogen) antibodies
diluted 1:10,000 in milk blocking solution. Development was
done using Clarity Western ECL Substrate (Bio-Rad), and
staining was visualized using a CCD camera (Bio-Rad).
Brain Section Preparation
Wild-type adult male C57Bl6/J mice were anaesthetised with
an intraperitoneal injection of 0.5 mg/g body weight pentobar-
bital sodium (Apoteksbolaget). Transcardiac perfusion was
performed using phosphate-buffered saline (PBS) (137.0 mM
NaCl, 2.70 mM KCl, 8.10 mM Na2HPO4) followed by 4 %
formaldehyde (HistoLab) fixation. The brain was dissected
and stored in 4 % formaldehyde overnight at 4 °C before
further processing. Seventy-micrometer free-floating brain sec-
tions were prepared by washing the brain twice in Tris-
buffered saline (TBS) (0.04 M Trizma HCl, 0.01 M Trizma
base, 0.15 M NaCl, pH 7.4) for 5 min followed by embedding
in 4% agarose gel (Pronadisa Conda). Sections were cut with a
vibratome Leica VT 1200S (Leica Microsystems). For 12-μm
coronal cryostat sections, the brains were incubated in 30 %
sucrose prior to freezing. Sections were cut in a cryostat (HM
560, Microm International).
Non-fluorescent Staining on Free-Floating Mouse Brain
Sections
All chemicals were purchased from Sigma-Aldrich, unless oth-
erwise stated. Seventy-micrometer brain sections from two
mice were rinsed in TBS 4 × 8 min before and after incubation
in 10 % MeOH and 3 % H2O2 (Merck Millipore) in TBS for
10 min. Sections were incubated in 1 % blocking reagent
(Roche Diagnostics) for 1 h followed by primary antibody
incubation with anti-MFSD1 (1:1000) and anti-MFSD3
(1:1000) diluted in supermix (0.25 % gelatine, 0.5 % Triton
X-100 in TBS) overnight at 4 °C. Sections were rinsed in
TBS 2 × 1 + 4 × 8 min and incubated in secondary antibody
(biotinylated goat-anti-rabbit IgG (H + L), Vector laboratories)
diluted 1:400 in supermix for 1 h. Sections were rinsed in TBS
5 × 8 min before and after incubation in ABC kit (Reagent A,
Reagent B (Vectastain, Vector Laboratories) and diluted 1:800
in supermix for 1 h. Sections were incubated in 0.05 % 3.3
diaminobenzidine tetrahydrochloride, 0.35 % NiCl and
0.015 % H2O2 and rinsed 4 × 5 min in TBS before mounted
on gelatinized microscope slides (Menzel Gläser). Samples
were dehydrated in 70 and 95 % EtOH for 5 min, 100 %
EtOH (Solveco) for 10 min prior xylene incubation for
20 min. Slides were mounted in DPX Mounting for histology
with micro cover slides Superfrost Plus (Menzel Gläser).
Sections were analysed using a Mirax Pannoramic midi scan-
ner with the Pannoramic Viewer software version 1.15.4 RTM
(3dHistech).
Immunohistochemistry on Embryo and Adult Brain
Sections
Fluorescent immunohistochemistry was performed on
cryostat-sectioned brains. Sections were washed in PBS
followed by primary antibody incubation overnight. All anti-
bodies were diluted in supermix. Anti-MFSD1 (1:50) and
anti-MFSD3 (1:50) were used to label the proteins. They were
co-stained with the neuronal nuclear marker anti-NeuN (1:400
mouse, cat. no: MAB377, Millipore) (Mullen et al. 1992), the
astrocyte marker anti-GFAP (1:400 mouse, cat. no: MAB360,
Millipore) (Reeves et al. 1989) and the dendritic marker anti-
MAP2 (1:400 mouse, cat. no: M4403, Sigma-Aldrich) (Izant
and McIntosh 1980). After additional PBS washes, slides
Fig. 1 Evolutionary conservation of MFSD1 and MFSD3 and their
sequence similarities to SLCs. a The phylogenetic tree was calculated
using a Bayesian approach. Orthologues of MFSD1 and MFSD3 are
marked in red. Species abbreviations: ac Anolis carolinensis, dm
Drosophila melanogaster, dr Danio rerio, ga Gasterosteus aculeatus,
gg Gallus gallus, mm Mus musculus, tr Takifugu rubripes, xt Xenopus
tropicalis. The tree was used as base when creating the schematic
representation of the branching order (b)
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were incubated with secondary antibody for 2 h at RT.
Secondary antibodies used are as follows: alexa 488 goat-an-
ti-rabbit, alexa 488 donkey-anti-goat and alexa 594 donkey-
anti-mouse (Invitrogen) diluted 1:400. PBS washes followed
by 10min DAPI staining (1:3000 in PBS, Sigma-Aldrich) and
additional washes before mounted in Mowiol anti-fade media
(25 gMowiol 4–88 in 100-ml 1× PBS, pH 8.0, 50ml glycerol,
3 ml of 1 % thimerosal and 100 μg/ml n-propyl gallate in
(Sigma-Aldrich)). Images were taken using an Olympus mi-
croscope BX53 with an Olympus DP73 camera. The micro-
graphs were acquired by cellSens Dimension software.
Immunocytochemistry on Embryonic Primary Cortex
Cells
Embryos at days 14–15 were retrieved and their cortices were
used to create embryonic primary cell cultures as described in
(Perland et al. 2016). Briefly, pregnant females were euthanized
by cervical dislocation followed by embryo retrieval. The cor-
tices were dissected and dissociated using both chemical and
mechanical procedures followed by filtration to ensure single
cells before seeding the cells in plating media (DMEM-F12
(Gibco), 10 % FBS (Gibco), 2 mM L-glutamine (Invitrogen),
1 mM Na-pyruvate (Invitrogen) and 1 % penicillin/
streptomycin (Invitrogen)) in a density of 7.5 × 104 cells on
poly-L-lysine (Sigma-Aldrich)-coated cover slips. Cells were
incubated for 3 h at 37 °C, 5 % CO2 before the media was
changed to growth media (Neurobasal-A (Gibco), 2 mM L-
glutamine, 1 mM Na-pyruvate, 1 % penicillin/streptomycin
and 2 % B27 (Invitrogen)). Seventy-five percent of the media
was changed every 3–4 days and at day 10, the cells were fixed
in 4 % formaldehyde for 1 h and rinsed in PBS.
Immunocytochemistry was performed as previously de-
scribed in (Perland et al. 2016). Anti-MFSD1 (1:50) and
anti-MFSD3 (1:50) were co-stained with: anti-PAN
Neuronal marker (1:300, mouse, cat. no: MAB2300,
Millipore); anti-Lamp2 (1:100, rat, cat.no: Ab13524,
Abcam) (Chen et al. 1985) and anti-Golgi58K (1:100, goat,
cat. no: Ab19072, Abcam) (Anthony and Gietzen 2013).
MFSD1 was additionally stained together with anti-
Synaptotagmin (1:100, mouse, cat. no: MAB5200,
Millipore) (O’Connor and Lee 2002) and anti-synaptophysin
(1:200, mouse, cat. no: Ab8049, Abcam) (McMahon et al.
1996). Images were taken using a LSM710 super resolution
microscope (Zeiss) with the Black Zen software. Z-stacks
were acquired and merged into 2D images using Fiji Image
J (Schindelin et al. 2012; Schindelin et al. 2015).
Amino Acid Deprivation on Primary Mouse Embryonic
Cortex Cells
Starved primary cortex cells were deprived of the following
amino acids: glycine, L-alanine, L-asparagine, L-glutamine,
L-histidine, L-isoleucine, L-leucine, L-serine and L-valine.
Control medium was prepared by adding 2.0 mM
GlutaMAX to EBSS medium (Gibco, Life technologies) and
glycine, L-alanine, L-arginine, L-asparagine, L-cysteine, L-
histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-
phenylalanine, L-proline, L-serine, L-threonine, L-trypto-
phan, L-tyrosine and L-valine (Sigma-Aldrich) was added in
the same concentrations as in the Neurobasal-A medium.
Medium for the amino acid-deprived cells was prepared by
adding L-arginine, L-cysteine, L-lysine, L-methionine, L-phe-
nylalanine, L-proline, L-threonine, L-tryptophan and L-
tyrosine (Sigma-Aldrich) in the same concentrations as in
the Neurobasal-Amedium to the Earle’s balanced salt solution
(EBSS) medium. Both the control and starvation mediumwas
supplemented with 1.0 mM sodium-pyruvate, 1 % penicillin/
streptomycin, 2 % B-27® (50X), 4× MEM vitamin solution
(100×) (Gibco, Life technologies) and 10.9mMHEPES (1M)
buffer solution (Gibco, Life technologies). The experiment
was run in triplicates in each treatment group. The cells were
treated in the limited amino acid medium or the complete
amino acidmedium for 3, 7, or 12 h before RNAwas extracted
using RNeasy Midi Kit (QIAGEN), following the manufac-
tures protocol. cDNA synthesis and qPCR were run and
analysed as previously described. cDNA from the triplicates
in each treatment group were pooled and the geometric mean
of the expression of the housekeeping genes Gapdh, H3a and
Actbwere used for normalization. Unpaired t tests were run to
calculate the differences in gene expression between the nor-
mally fed and the starved cells, *p ≤ 0.05, **p ≤ 0.01 and
***p ≤ 0.001 were used as significance levels. Normalized
expressions ±SD were plotted.
Results
Phylogenetic Analysis Showed Clusters with SLCs
We inferred the phylogenetic relationship between plausible
orthologues to human MFSD1 and MFSD3 using the
Bayesian approach to obtain the tree in Fig. 1a. MFSD1 and
MFSD3 were found to be present in chordates, whereas
MFSD1 also was detected in Drosophila melanogaster.
MFSD1 and MFSD3 also clustered with SLCs of MFS type
and other MFSD proteins, suggesting they are atypical puta-
tive SLCs. Interestingly,MFSD1wasmostly related to SLC29
family members, whereas MFSD3 grouped together with
SLC33 (Fig. 1a). However, note also that SLC29A4 diverged
evolutionary from the other SLC29 members, since it clus-
tered with the SLC19 family (Fig. 1a) and was thus more
related to MFSD3, than MFSD1. In Fig. 1b, we depicted the
schematic branching order between SLC families and how
they interrelate with known MFSD proteins. From this, it is
evident that MFSD1 is most closely related to the facilitative
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nucleoside transporter SLC29 family; while MFSD3 clusters
with SLC33, the acetyl-CoA transporter family (Fig. 1b).
Regarding the MFSD proteins, they phylogenetically group
together with SLCs in an arbitrary order, enhancing the hy-
pothesis that they, in fact, are membrane-bound transporters
belonging to various SLC families.
Secondary Structures and Sequence Identity with Known
SLC Transporters
The TMS prediction provided a probability plot, showing
transmembrane helices, and it revealed 12 TMS for both
MFSD1 and MFSD3 (Fig. 2a, b). All identified TMS did
not meet the criterion for highest probability, suggesting
that the amino acid sequences are diverging from the more
common TMS structures. To compare the MFSD1 and
MFSD3 proteins with known SLCs, we aligned their se-
quences with members of the phylogenetically closest fam-
ily, SLC29 and SLC33, respectively. The largest MFSD1
splice variant shared following sequence identity with
SLC29 family members; 6.2 % of the sequence was iden-
tical with SLC29A1, of which they shared 50 amino
acids, 18.5 % with SLC29A2 (116 identical aa, depicted
in grey in Fig. 2a), 16.4 % with SLC29A3 (101 identical
aa) and 7.9 % with SLC29A4 (64 identical aa). MFSD3
was aligned with SLC33A1 (Fig. 2b.), displaying 19.5 %
sequence identity, with 114 identical amino acids.
Fig. 2 Secondary structures of
MFSD1 and MFSD3. The amino
acids in the MFSD1 (a) and
MFSD3 (b) proteins are depicted
as 12 TMS regions (I–XII). As
MFSD1 and MFSD3 are closely
related to the SLC29 and SLC33
family, we aligned the proteins to
study sequence identities. The
grey circles represent the identical
amino acids after alignment
between MFSD1 and SLC29A2
and MFSD3 with SLC33A1. The
tables represent the sequence
identities obtained from global
pairwise alignments between
MFSD1 and SLC29members and
MFSD3 and SLC33A, where the
amino acids in brackets are the
once identical between the
proteins
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Homology Models for MFSD1 and MFSD3
Also with homology modelling, 12 possible transmembrane
helices for both MFSD1 (Fig. 3a, b) and MFSD3 (Fig. 3c, d)
were identified. The homology structures were aligned against
MFS protein templates, where theMFSD1model had a global
model quality estimation (GMQE) value of 0.47 while the
MFSD3 model had a GMQE value at 0.5. GMQE scale range
from 0 to 1, to indicate the credibility of the models. Looking
at the tertiary structures from top view (Fig. 3b, d), both pro-
teins seemed to form a pore, through which a substrate possi-
bly could be transported. Based on the modelling, both the N-
and C-terminals were in the cytoplasm.
RNA Expression in Wild-Type Mice
The gene expressions of Mfsd1 and Mfsd3 were analysed in
organs from C57BL/6 mice, using qPCR.Mfsd1 was detected
throughout the panel, with high relative expression in periph-
eral organs such as kidney (1.17 ± 0.12) and liver (0.85 ± 0.08)
(Fig. 4a). Of the central areas, highest expression was mea-
sured in brainstem (0.19 ± 0.01) and spinal cord (0.13 ± 0.02)
(Fig. 4a). Mfsd3 displayed abundant expression throughout
the periphery and the CNS with high relative levels in periph-
eral organs such as liver (2.19 ± 0.25), kidneys (0.56 ± 0.04)
and ovaries (0.53 ± 0.02) and central areas such as hypothal-
amus (0.56 ± 0.06), thalamus (0.40 ± 0.05) and spinal cord
(0.36 ± 0.05) (Fig. 4b).
Western Blot Verifies Antibodies Specificities
To verify the specificity of the commercially available anti-
bodies, western blot was run on fractionated mouse brain. The
anti-MFSD1 antibody bound to one band at size 58 kDA
(Fig. 4c), which agrees well with the predicted mouse splice
variant at 51 kDA (Ensembl no: ENSMUST00000029344).
The anti-MFSD3 antibody bound proteins at approximate size
50 kDa (Fig. 4d) which corresponds to the mouse splice var-
iant at size 43 kDA (Ensembl no: ENSMUST00000019224).
Hence, both antibodies bound proteins at sizes within
±10 kDA from the predicted annotated size so the western
blot verified the specificities of the antibodies.
Fig. 3 Homology modelling. The tertiary structures of MFSD1 (a, b)
andMFSD3 (c, d) revealed 12 transmembrane regions, marked 1–12. a, c
The side-views of the homology models. b, d The top-view, in which a
possible substrate pore, marked in yellow, can be seen.MFS proteins were
used as templates when building the homology models
Fig. 4 qPCR measurements of Mfsd1 and Mfsd3 in wild-type mice and
antibody verification. The relative mRNA expression levels (normalized
mean ± SD) ofMfsd1 (a) andMfsd3 (b) in organs fromC57BL/6 mice are
displayed in the column charts. n = 5 per organ. For protein detection,
commercially bought antibodies were used and their specificity was ver-
ified with western blot prior staining. Anti-MFSD1 bound proteins at size
58 kDa (c) and anti-MFSD3 revealed one band at size 50 kDa (d). The
band sizes corresponded well with predicted protein sizes; hence it veri-
fied the antibody specificity
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Bright Field Immunostaining to Screen for Protein
Distribution
Non-fluorescent immunohistochemistry on 70-μm free-
floating coronal mouse brain sections was performed
using the anti-MFSD1 (Fig. 5, overview pictures (a–e)
and close-up pictures (f–o)) and the anti-MFSD3 antibod-
ies (Fig. 6, overview pictures (a–e) and close-up pictures
(f–o)). MFSD1 staining was seen in cortex, striatum hip-
pocampus, hypothalamus, thalamus, brainstem and cere-
bellum. Based on morphology, MFSD1 labelled various
parts of the cell body and different cell types. As seen in
the magnified images, the MFSD1 antibody stained cere-
bral cortex areas such as piriform cortex (Fig. 5f) and
primary somatosensory barrel (Fig. 5h). Staining was also
seen in striatum (Fig. 5g), thalamic nuclei (Fig. 5i) and
the arcuate hypothalamic nucleus (Fig. 5j). In addition to
the soma staining, MFSD1 labelled projections seen in the
hippocampus (Fig. 5k, m) and cells in midbrain areas like
the red nucleus (Fig. 5l), together with cells in brainstem
areas such as the facial nucleus (Fig. 5n). Also, the
Purkinje cell layer in cerebellum was stained by the
MFSD1 antibody (Fig. 5o).
Immunostaining with the MFSD3 antibody was more ho-
mogenous and abundant thanMFSD1 staining. MFSD3 stain-
ing was located in, e.g. cortex, striatum, hippocampus, hypo-
thalamus, thalamus, cerebellum (Fig. 6a–e); specifically found
in striatum, caudate putamen (Fig. 6f) and in the area around
the lateral ventricles (Fig. 6g). There was also homogenous
staining throughout cerebral cortex (Fig. 6h) and piriform cor-
tex (Fig. 6i). In addition, staining was located in all hippocam-
pus fields, together with dentate gyrus (Fig. 6j, m).
Hypothalamic staining was detected in the areas around the
third ventricle, with high expression in arcuate hypothalamic
nucleus (Fig. 6k), as well as in midbrain areas lateral of the
midline (Fig. 6l) and in the brainstem (Fig. 6n). Finally, cere-
bellar staining was detected in for example the Crus 1 area
(Fig. 6o).
Fig. 5 Bright field MFSD1
protein screening in coronal
mouse brain sections. DAB
immunohistochemistry for
MFSD1 on free-floating mouse
brain sections with overview
pictures (a–e), close-up pictures
with scale bars of 200 μm (f–o).
The Bregma regions correspond
to the mouse brain in (Franklin
and Paxinos (2007). There are
overview micrographs in which
the magnifications are marked
with dashed lines: (a) Bregma
0.38 mm, (b) Bregma −1.22 mm,
(c) Bregma −1.82 mm, (d)
Bregma −3.28 mm and (e)
Bregma −5.80 mm. The
magnified images are as
followsed: (f) piriform cortex and
(g) caudate putamen (striatum);
(h) primary somatosensory barrel
cortex and (i) ventral
posteromedial thalamic nucleus;
(j) the arcuate hypothalamic
nucleus and (k) hippocampus
fields CA1, CA2 and CA3. Large
cells were seen in the red nucleus
(l), both in the parvocellular and
magnocellular part. Projections
are depicted in the hippocampus
region CA1 (m) and cells in the
facial nucleus (n). Finally, the
Purkinje cell layer in the
cerebellum (o) is shown
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Fluorescent Co-staining Reveals Specific Subcellular
Neuronal Staining
To study in what cell types MFSD1 and MFSD3 were
expressed, they were co-labelled with cellular markers
on mouse brain sections. Staining revealed overlap with
the neuronal marker NeuN (Fig. 7a, b), but not with the
astrocytic marker GFAP (Fig. 7c, d) or the dendritic mark-
er MAP2 (Fig. 7e, f). The subcellular location of the
MFSD1 and MFSD3 was studied in embryonic primary
cortex cells using immunocytochemistry. The anti-
MFSD1 antibody co-stained with PAN (Fig. 8a) in a sub-
set of neurons. Partial overlap with the vesicular marker
synaptophysin (Fig. 8b) and the synaptic vesicle marker
synaptotagmin (Fig. 8c) were observed, suggesting co-
expression in synapses. No overlap was detected with
the lysosome marker Lamp2 (Fig. 8d) or the Golgi marker
Golgi58K (Fig. 8e). For MFSD3, co-staining was detected
with PAN (Fig. 8f), but not with the Lamp2 (Fig. 8g) or
the Golgi58K marker (Fig. 8h).
Gene Expression Following Amino Acid Deprivation
in Mouse Embryonic Cortex Cells
Mature mouse embryonic cortex cells were cultured in limited
or complete amino acid medium for 3, 7, or 12 h, followed by
gene expression measurements for Mfsd1 and Mfsd3.
Following amino acid limitation, Mfsd1 was upregulated at
3 h (p = 0.0249), 7 h (p = 0.0103) and 12 h (p = 0.0077) of
treatment compared with amino acid-treated control cells
(Fig. 9a) while Mfsd3 was not altered at any time (3 h
(p = 0.0950), 7 h (p = 0.5418) and 12 h (p = 0.2499)) (Fig. 9b).
Gene Expression after Changed Energy Homeostasis
As altered expressions were detected after amino acid starva-
tion in cortex cells, we found it interesting to study it in vivo as
well. The gene expressions were measured in cortex and other
brain areas, from mice following starvation and HFD. We
included brainstem, cerebellum, cortex, hypothalamus and
striatum in the analyses. After 24-h starvation, Mfsd1 was
Fig. 6 Bright field MFSD3
protein screening in coronal
mouse brain sections. MFSD3
staining on free-floating sections
displayed a homogenous staining
pattern. Here are overview
pictures (a–e) and enlarged
images with scale bars of 200 μm
(f–o) shown. (a) Bregma 0.02
mm, (b) Bregma −1.06 mm, (c)
Bregma −1.58 mm, (d) Bregma
−2.80 mm and (e) Bregma −5.80
mm display the overall staining,
including dashed lines that
indicates the magnifications.
Staining was located to at the (f)
caudate putamen and (g) around
the lateral ventricle; (h) motor and
primary somatosensory areas and
(i) piriform cortex; (j) the
hippocampus, fields CA1, CA2
and CA3 and dentate gyrus, and
(k) arcuate hypothalamic nuclei
around the third ventricle.
Staining was also found around
the dorsal third ventricle, in the
area anterior pretectal nucleus
area (l). Staining was also seen in
midbrain areas and (m) the
dentate gyrus. Finally, cells were
seen in the brainstem, e.g. in the
facial nucleus (n), and in the
cerebellum (o), e.g. Crus 1 area
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upregulated in brainstem (p = 0.0001) while downregulated in
cortex (p = 0.0358) and striatum (p = 0.0333) (Fig. 9c) com-
pared with controls. Mfsd3 was upregulated in brainstem
(p = 0.0064) and cerebellum (p = 0.0037) and downregulated
in hypothalamus (p = 0.00145) (Fig. 9d). Following HFD,
Mfsd1 was downregulated in brainstem (p = 0.0124) and hy-
pothalamus (p = 0.0181) (Fig. 9e) and Mfsd3 was downregu-
lated in brainstem (p = 0.0049) (Fig. 9f).
As interesting effects were measured in the brain areas, new
mice were exposed to starvation and HFD. These brains were
sectioned according to the schematic brain (Fig. 9g), adapted
from (Perland et al. 2016). Both genes responded in similar
fashion to starvation with downregulation in sections 2
(Mfsd1 p = 0.0067; Mfsd3 p = 0.0207) and 3 (Mfsd1
p = 0.0067; Mfsd3 p = 0.0037) (Fig. 9h, i). In addition, Mfsd1
was upregulated in section 1 (p = 0.0035) and downregulated in
section 7 (p = 0.047) (Fig. 9h) after starvation. In the obese
mice, the mRNA levels ofMfsd1were upregulated in section 1
(p = 0.0127) compared with the controls and downregulated in
section 3 (p = 0.0442) (Fig. 9j), whereas the expression of
Mfsd3 was reduced in all but section 7; sections 1
(p = 0.0002), 2 (p = 0.009), 3 (p = 0.0009), 4 (p = 0.0005), 5
(p = 0.006) and section 6 (p = 0.0002) (Fig. 9k).
Discussion
In this work, we identified and characterized two novel pro-
teins, MFSD1 and MFSD3, and presented their histological
expression pattern in the mouse brain, providing a solid
ground for further work to be based on. The fact that they
are named according to the MFSD nomenclature suggests that
they are atypical SLCs (Fredriksson et al. 2008) and hence
possibly transporters. Both proteins also belong to the major
facilitator superfamily (MFS), which is the largest group of
facilitators and secondary active transporters (Law et al. 2008;
Pao et al. 1998; Reddy et al. 2012; Saier et al. 1999) in several
phylum (Pao et al. 1998). As MFSD1 and MFSD3 contain
MFS motifs, we performed a phylogenetic analysis showing
their similarity to SLCs of MFS type and other MFSD pro-
teins, strengthening the hypothesis that they are indeed trans-
porters. The HUGOGene Nomenclature Committee (HGNC)
classifies SLCs into families based on function, homology or
phenotype (Gray et al. 2016), where family members share
20 % sequence identity with other members (Hediger et al.
2004). This means that neither MFSD1 nor MFSD3 can be
classified into their phylogenetically closest SLC family, as
investigated here. However, SLC29A4 clustered phylogenet-
ically more closely to MFSD3 than to its own family, SLC29
(Fig. 1a), while it shared highest sequence identity with
SLC29 members. This means that MFSD1 and MFSD3 could
still share more than 20 % sequence identity to other SLC
members and hence belong to that SLC family.
Based on the secondary and tertiary structures, we predict-
ed MFSD1 and MFSD3 to have 12 TMS each, which is com-
mon for MFS proteins (Law et al. 2008), as they all derived
from the same evolutionary origin (Reddy et al. 2012). An
interesting note is that SLC29 members, the closest to
Fig. 7 MFSD1 and MFSD3 are
expressed specifically in neurons.
To determine cell type expression,
fluorescent immunostaining on
coronal mouse brain sections,
with nuclear DAPI staining were
run. This revealed co-staining be-
tween MFSD1 (a) and MFSD3
(b), with the neuronal marker
NeuN as seen in the merged im-
ages. No overlap could be seen
with either the astrocytic marker
GFAP (c, d) or the dendritic
marker MAP2 (e, f). Micrographs
were acquired using a fluores-
cence Olympus microscope
BX53 with an Olympus DP73
camera
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MFSD1, are predicted to have 11 TMS regions (Baldwin et al.
2004; Valdes et al. 2014; Young et al. 2008), even though they
are SLCs ofMFS type, which could explain why the sequence
identities to Mfsd1 were relatively low. As phylogenetically
related SLCs generally share similar substrates (Schlessinger
et al. 2010), it is plausible that MFSD1 and MFSD3 transport
organic substrates since they clustered with SLCs having or-
ganic substrates. MFSD3 is a predicted Acetyl-CoA transport-
er according to Kyoto Encyclopaedia of Genes and Genomes
(Kanehisa et al. 2016), and we showed that it shares evolu-
tionary origin and relatively high sequence identity with
SLC33A1, a known Acetyl-CoA transporter (Hirabayashi
et al. 2013), enhancing the hypothesis of organic substrate
profiles. However, preferable substrates for MFSD1 and
MFSD3 still need to be elucidated.
The homology models of MFSD1 and MFSD3 enforce the
possibility that they are permeases. Both the C- and N-
terminals are predicted to be located in the cytosolic side of
the membrane, which is in accordance with previous reports
regarding MFS proteins (Yan 2013). Also, when looking at
the 3D structures, both seem to fold into a cylinder (seen in
Fig. 3b, d), through which a potential substrate could be shuf-
fled. However, based on global model quality estimation
(GMQE), the MFSD1 and MFSD3 models both scored
around 0.5 on the 0–1 scale, where higher values indicates a
more probable model. Therefore, it is important to remember
that these are predications and the actual structures still need to
be determined.
With fluorescent double-staining, we demonstrated that
both proteins were specifically expressed in neurons within
the mouse brain. When looking at the MFSD1 staining, neu-
ronal projections were labelled; presumably, they were axonal
projections as no co-staining was detected with the dendritic
microtubule marker MAP2. In the primary cells, MFSD1
Fig. 8 Subcellular localization of MFSD1 and MFSD3. The subcellular
distribution of MFSD1 and MFSD3 was studied using fluorescent
immunostaining in mouse embryonic primary cortex cells. MFSD1 co-
localized well with PAN (a) and partial overlap with synaptophysin (b)
and synaptotagmin (c) was detected. No co-staining was seen with
Lamp2 (d) or Golgi58K (e). MFSD3 co-localized with PAN (f), but not
with Lamp2 (g) or Golgi58K (h). Micrographs were acquired using an
LSM710 super resolution microscope. Scale bars represent 10 μm
Fig. 9 mRNA expression changes after altered energy intake in primary
cells and the mouse brain. Primary mouse embryonic cortex cells were
deprived of nine amino acids for 3, 7, or 12 h while the control cells had
access to these amino acids. The gene expression forMfsd1 (a) andMfsd3
(b) was measured. The graphs display the relative mRNA expressions
(±SD), (*p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001). Mice were assigned tree
different food paradigms before euthanasia; (1) normal chow (control),
(2) 24-h starvation and (3) high-fat diet (HFD). The gene expression was
measured for Mfsd1 and Mfsd3 in brainstem, cerebellum, cortex, hypo-
thalamus and striatum after starvation (c, d) and HFD (e, f) where n = 4
per group. Brains from additional mice (controls, n = 6, starved n = 4 and
HFD n = 6) were excised into seven sections (g), image adjusted from
(Perland et al. 2016). Expression levels after starvation are depicted h for
Mfsd1 and i forMfsd3 and after HFD forMfsd1 (j) andMfsd3 (k).Gapdh,
H3a and Actb were used as reference genes. *p ≤ 0.0493, **p ≤ 0.00998
and ***p ≤ 0.001 after Bonferroni correction
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overlapped with the neuronal marker PAN in a subset of neu-
rons. There was also partial overlap with the vesicular markers
synaptophysin and synaptotagmin, which is possible if
MFSD1 is located in the plasma membrane. If the epitopes
for the antibodies are in close proximity to each other, it is
likely to see colour overlay. However, as there was no com-
plete overlap, we found it most likely thatMFSD1was present
along the plasma membrane and not constricted to the active
zones. Interestingly, no overlap with the lysosomal marker
Lamp2 was detected, as previously suggested in stained
HeLa cells (Palmieri et al. 2011). Some overlap signal could
be seen between the MFSD1 and Lamp2 markers before
performing the super resolution processing. However, when
looking through the images in the Z-stack, the colours were
located in different focus points in the cells. No colour overlay
was detected in the final image because MFSD1 expression
was probably in the plasma membrane while Lamp2 was
intracellular.
MFSD3 had a broader staining pattern than MFSD1 and
was located in the membrane in most neurons. Note that anti-
MFSD3 also bound epitopes having similar intracellular mor-
phology as the Golgi marker; however no significant overlay
between the markers was detected looking through the Z-
stacks. As proteins are being processed for further transport
in Golgi, it is possible to get staining there, even though the
Golgi is not the final location of the protein. Therefore, it is
most likely that MFSD3 is functionally active in the plasma
membrane and not in any intracellular organelles.
It has previously been reported that several genes encoding
characterized amino acid transporters from the SLC superfam-
ily, are upregulated following amino acid deprivation in cells,
e.g. Slc38a2 (Palii et al. 2006), Slc7a1 (Fernandez et al. 2003),
Slc7a5 (Padbury et al. 2004), Slc7a11 (Sato et al. 2004),
Slc1a4 and Slc3a2 (Lee et al. 2008). However, not all amino
acid transporters are regulated in response to amino acid star-
vation and the increased expression levels detected for Mfsd1
do not necessarily mean that it is an amino acid transporter.
MFSD1 is a predicted sugar transporter (Kanehisa et al. 2016),
and both glutamine (Nurjhan et al. 1995) and alanine (Felig
et al. 1970) can be constituents in glucose synthesis. Hence,
also transporters with substrates that are synthesized from
amino acids can be transcriptionally upregulated. However,
even though MFSD3 is a predicted acetyl-CoA transporter
(Kanehisa et al. 2016) and acetyl-CoA has amino acids as
precursors (Arrieta-Cruz and Gutierrez-Juarez 2016), it was
un-altered by the partial amino acid deprivation.
Half of all Slc genes are present in areas involved in energy
production and food consumption (Dahlin et al. 2009), as were
the case for MFSD1 andMFSD3. Looking at in vivo effects in
brain areas involved in metabolism, following changed nutri-
tional status, it indicated that expression of both genes was
affected. Mfsd1 was downregulated specifically in cortex and
striatum after starvation, which are both well-known areas
involved in food and reward pathways (Farr et al. 2016).
Mfsd1 reduction was also seen in three of the brain sections;
section 2 that included cortex, section 3, with e.g. the striatum
and section 7 with cerebellum and brainstem. Interestingly,
after starvation,Mfsd1 andMfsd3 were specifically upregulat-
ed in brainstem, that gate transmitting signals from peripheral
circulating hormones to the remaining brain (Mikulaskova
et al. 2016). Hence, the downregulation of Mfsd1 in section 7
could be due to effects in cerebellum, possibly the cerebellar-
hypothalamic circuits which convey signals from both hor-
mones and gastric vagal afferents to hypothalamic neurons
(Zhu andWang 2008). Both genes responded similarly to food
deprivation, but, after high-fat consumption,Mfsd1was stable,
while Mfsd3 was reduced extensively. Even if the two trans-
porters at first seem similar, with common ancestral back
ground, and expression in similar brain areas, they probably
have different roles in vivo.
For the in vivo study, we included specific brain areas and
larger brain sections. Since we know that Mfsd1 and Mfsd3
were specifically expressed in a subpopulation of cells, it is
possible that specific changes are diluted in the larger sample.
Analyses of brain sections are a good way to include whole
circuits as neurons can project beyond specific areas or nuclei.
Therefore, we found it interesting to study changes in mRNA
expression in both specific brain areas and larger brain sec-
tions, to get the best representation of actual functions.
We used the C57BL/6J mouse strain for the in vivo energy
homeostasis study since the mice responds in similar way as
humans regarding the metabolic syndrome (Collins et al.
2004). Therefore, there is the possibility that the measurable
effects after both starvation and HFD are due to secondary
effects such as stress and inflammation. However, it seems
that SLCs involved in the immune response are more fre-
quently induced during inflammation (Cellier 2013;
Sasawatari et al. 2011), whereas both Mfsd1 and Mfsd3 were
reduced. Hence, we found it most likely that the effects are
primarily due to food rather than inflammation or stress.
In conclusion, we have studied MFSD1 and MFSD3,
two novel atypical SLCs that phylogenetically clustered
with SLCs of MFS type. We displayed their abundant
mRNA expression and their location to the plasma
membrane in neurons. Finally, we demonstrated that
Mfsd1 and Mfsd3 mRNA levels were affected by altered
nutrition intake.
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